NCT05839574 - Letrozole add-on in the Treatment of Cesarean Scar Pregnancy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 30, 2022

Study Completion Date

October 30, 2023

Conditions

Cesarean Scar Pregnancy

Interventions

DRUG

MTX monotherapy

MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH), and subsequent hysteroscopic evacuation of products of conception (POC)

DRUG

MTX + letrozole add-on

MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH) + Letrozole in a daily dose of 5 mg (2 x 2.5 mg) orally for 10 days from day 0, and subsequent hysteroscopic evacuation of products of conception (POC)

Trial Locations (1)

31-501

Jagiellonian University Medical College, Department of Gynecology and Obstetrics, Clinic of Gynecological Endocrinology, Krakow

All Listed Sponsors

lead

Jagiellonian University

OTHER